SHOCKING: 7 - You Need To See This

Nike Is Back at Its 2014 Price and Still Isn’t Cheap, and Wall Street Expects Earnings to Fall Another 18%

Even at its lowest in 12 years, NKE stock has still not hit rock bottom.

Barchart · Aug 21

Ahead of Zoom Earnings, Here's What Barchart Data Says Comes Next for ZM Stock

Zoom is scheduled to report its fiscal Q2 earnings on Aug. 25. Options traders and Wall Street analysts are bullish on ZM shares heading into the quarterly release.

Barchart · Aug 21

Truist Just Upped Its Price Target on Snowflake Stock. Here's Why.

A Truist analyst sees further upside in Snowflake stock ahead. Here’s what he believes could drive SNOW shares higher.

Barchart · Aug 21

Is the VIX Inexpensive Going into the Historically Volatile Fall in 2026?

Through the first seven months of 2026, the VIX index has traded in a narrower range than in 2025. However, markets are moving into a season when stock market volatility often rears its ugly head. The VIX index at the 18 level could be inexpensive in August 2026.

Barchart · Aug 20

David Friedberg Says 1 Piece of SpaceX Could Be Worth a Trillion Dollars Inside 18 Months, ‘That I Think Funds All of the Rest of This’

Friedberg spoked about SpaceX on the All-In podcast earlier this month.

Barchart · Aug 20

This Stock’s Up 60% and Is a Buy If You’re Bullish on U.S. Housing

James Hardie Industries (JHX) demonstrates strong technical momentum. Shares are up 60% over the past year. Analyst sentiment is predominantly bullish, with 13 “Strong Buy” ratings and consensus price targets ranging from $33.50 to $65. JHX’s outlook is closely tied to the U.S. housing industry; building permit issuance is a...

Barchart · Aug 20

Huge Unusual Put Options Volume in Merck - Is MRK Stock Overvalued?

A Barchart report shows that despite recent strong Q2 results and a 10% spike in Merck stock today, an unusually large volume of put options has traded at a much lower strike price. Is MRK stock overvalued?

Barchart · Aug 19

This Stock’s Already Up Nearly 600% Over the Past Year

Spyre Therapeutics (SYRE) has surged more than 565% over the past year, driven by strong technical momentum. Shares are trading at a new 3-year high. SYRE maintains a 100% “Buy” technical opinion from Barchart. Short interest is elevated at 13.81% of float, highlighting volatility and the need for disciplined risk...

Barchart · Aug 19

Ahead of Alibaba Earnings, Here's What Barchart Data Says Comes Next for BABA Stock

Alibaba is set to report its fiscal Q1 earnings on Aug. 20. Here’s how the data suggests BABA shares will respond to the earnings event.

Barchart · Aug 19

Bull Call Spread Screener Results For August 19th

With stocks in bullish mode it’s a good time to run Barchart’s Bull Call Spread Screener.

Barchart · Aug 19